BGB-16673

DRUG7 trials

Sponsors

BeOne Medicines AG, BeiGene, BeOne Medicines, M.D. Anderson Cancer Center

Conditions

B-cell MalignancyChronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic lymphocytic leukemia (CLL)Chronic lymphotic leukemia and Small Lymphocytic lymphomaDLBCL UnclassifiableFollicular Lymphoma

Phase 1

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

RecruitingNCT05294731

BeiGeneB-cell Malignancy, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, DLBCL Unclassifiable +6

Start: 2022-05-06End: 2029-01-31Target: 146Updated: 2026-08-21

Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants

CompletedNCT06906809

BeiGeneHealthy Volunteers

Start: 2025-04-03End: 2025-10-13Updated: 2026-08-24

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

RecruitingCTIS2024-516234-35-00

BeOne Medicines AGRelapsed or Refractory B-Cell Malignancies

Start: 2025-10-15Target: 99Updated: 2026-01-14

Phase 2

A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Not yet recruitingNCT07508995

M.D. Anderson Cancer CenterChronic Lymphocytic Leukemia (CLL)

Start: 2026-09-01End: 2033-07-01Target: 40Updated: 2026-08-25

Phase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Active, not recruitingNCT06970743

BeOne MedicinesChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Start: 2025-05-29End: 2029-11-30Updated: 2026-08-24

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

RecruitingCTIS2024-518893-15-00

BeOne Medicines AGChronic lymphotic leukemia and Small Lymphocytic lymphoma

Start: 2025-07-29Target: 56Updated: 2026-01-14

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

RecruitingCTIS2025-522860-34-00

BeOne Medicines AGChronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL)

Start: 2025-12-16Target: 196Updated: 2026-01-21

Related Papers

Bgb-16673, a Selective BTK Degrader, Exhibits Deeper Inhibition of Cancer Cell Signaling Pathways and Better Efficacy in MCL Models

Blood2024-11-05

P1219: BGB-16673, A BTK DEGRADER, OVERCOMES ON-TARGET RESISTANCE FROM BTK INHIBITORS AND PRESENTS SUSTAINABLE LONG-TERM TUMOR REGRESSION IN LYMPHOMA XENOGRAFT MODELS

HemaSphere2023-08-019 citations

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)

HemaSphere2023-08-017 citations